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Introduction: Osteopontin (OPN) is a malignancy-associated glycoprotein that contributes functionally to tumor
aggressiveness. In metastatic breast cancer, we previously demonstrated that elevated OPN in primary tumor
and blood was associated with poor prognosis.
Methods: We measured OPN in plasma by ELISA, and in tumors by immunohistochemistry, in 624 (94%) and
462 (69%), respectively, of 667 postmenopausal women with hormone responsive early breast cancer treated by
surgery followed by adjuvant treatment with tamoxifen +/− octreotide in a randomized trial (NCIC CTG MA.14;
National Cancer Institute of Canada Clinical Trials Group Mammary.14).
Results: Plasma OPN was measured in 2,540 samples; 688 at baseline and 1,852 collected during follow-up. Mean
baseline plasma OPN was 46 ng/ml (range 22.6 to 290) which did not differ from normal levels. Mean percentage OPN
tumor cell positivity was 33.9 (95% CI: 30.2 to 37.9). There was no correlation between plasma and tumor OPN values.
In multivariate analysis, neither was associated with event-free survival (EFS), relapse-free survival (RFS), overall survival
(OS), bone RFS or non-bone RFS. An exploratory analysis in patients with recurrence showed higher mean OPN plasma
levels 60.7 ng/ml (23.9 to 543) in the recurrence period compared with baseline levels.
Conclusions: The hypothesis that OPN tumor expression would have independent prognostic value in early breast
cancer was not supported by multivariate analysis of this study population. Plasma OPN levels in women with
hormone responsive early breast cancer in the MA.14 trial were not elevated and there was no evidence for prognostic
value of plasma OPN in this defined group of patients. However, our finding of elevated mean OPN plasma level
around the time of recurrence warrants further study.
Trial registration: NCT00002864, http://clinicaltrials.gov/show/NCT00002864Introduction
Osteopontin (OPN) is a secreted integrin-binding glyco-
phosphoprotein produced in a variety of tissues and cell
types, and its association with cancer has been well doc-
umented [1-4]. Our studies, and those of others, have
demonstrated that OPN contributes functionally to ag-
gressive cell behavior, tumor progression and metastasis.
Although OPN is not tumor-specific, its potential as a
tumor marker has been described in many malignancies,
including breast cancer [2-6].* Correspondence: ann.chambers@Lhsc.on.ca
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reproduction in any medium, provided the orWhen measured by immunohistochemistry (IHC),
OPN expression in breast cancer tissue has been doc-
umented both in tumor cells and infiltrating host cells
[7]. In a cohort of 154 patients with lymph node nega-
tive breast cancer, we reported that OPN immunopo-
sitivity in tumor cells, using a semi-quantitative IHC
scoring system, was significantly associated with decreased
disease-free and overall survival [7]. Similarly, Rudland’s
group reported an association between OPN positivity
and poor prognosis in early breast cancer, also using a
semi-quantitative IHC scoring system [8-10].
Using an ELISA (enzyme linked immunosorbent assay)
that we previously developed and clinically validated
[11-13], we demonstrated that compared with levels inal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ment for primary breast cancer, plasma OPN levels in
women with metastatic breast cancer were elevated and
associated with worse survival [11].
In the mid-1990s, we initiated a series of studies in
early and metastatic breast cancer to further explore the
potential of OPN as a biomarker in tumor tissue and
blood. We have already reported [14] the results of one
prospective study, which confirmed our earlier results
and showed that 99/158 (63%) of women at first presenta-
tion with metastatic breast cancer had elevated levels of
plasma OPN, and in multivariate analysis elevated OPN
was associated with worse overall survival (P = 0.03).
Thus, elevated OPN levels in both tumor tissue and
blood are well-documented to be associated with poor
outcome in the setting of metastatic breast cancer [1-5].
However, much less is known about the prognostic sig-
nificance of OPN in early breast cancer or when OPN
levels rise during breast cancer progression. We thus
identified the Mammary (MA).14 phase III clinical trial
from the National Cancer Institute of Canada Clinical
Trials Group (NCIC CTG) [15], as an opportunity to ad-
dress these questions. MA.14 provided us with a source
of blood and breast tumor tissue samples along with reli-
able patient data, from women with hormone responsive
early breast cancer in the context of a well-controlled
clinical trial. We hypothesized that there would be a rela-
tionship between baseline tumor and plasma levels of
OPN, that both would have prognostic value in early
breast cancer, and that breast cancer recurrence would
be associated with elevated plasma OPN levels.
Methods
NCIC CTG MA.14 clinical trial
In September 1996, the NCIC CTG opened a phase III
clinical trial (MA.14) evaluating the survival benefit of
a somatostatin analogue, octreotide Long-Acting Release
formulation (LAR), added to tamoxifen in postmenopausal
women with early stage hormone responsive breast cancer.
Collection of serum, at baseline and several time-points
thereafter, for assay of multiple metabolic markers of insu-
lin resistance, was an integrated secondary objective. All
patients enrolled in the MA.14 trial provided written
informed consent before participation, and ethics approval
was obtained by all participating centers, as previously
detailed in the primary trial report [15]. For our OPN
correlative study, a protocol amendment in November
1998 allowed us to add serial plasma collection for OPN,
and we also were permitted to access primary tumor paraf-
fin blocks/slides for OPN IHC studies. Postmenopausal
women with operable early breast cancer (T1-3, N0, M0)
stratified by hormone receptor status were eligible for the
MA.14 trial. Tamoxifen 20 mg/day was given for five years
in both arms, and octreotide LAR 90 mg intramuscularly(IM) monthly was given for two years in the experimental
arm. Modifications in design related to octreotide LAR
toxicity are described in the main trial report [15]. Recruit-
ment started in September 1996, and the trial closed in
August 2000 with the accrual of 667 women.
Despite excellent preclinical rationale for the anti-
tumor actions of somatostatin analogues, small clinical
studies showing breast cancer regression and evidence of
greater suppression of insulin-like growth factor by
octreotide added to tamoxifen, there was no significant
benefit for the combination in terms of event-free sur-
vival (HR (hazard ratio) 0.93, P = 0.62), relapse free sur-
vival (HR 0.84, P = 0.31) and overall survival (HR 0.97,
P = 0.86) at a median follow-up of 7.9 years. Five-year
event-free survival for all patients was around 78%.
There was no evidence of any significant differences in
OPN levels by treatment arm, at any time points and,
thus, in our OPN analyses we present data combined
from both arms of the trial.
Sample collection
The plasma sample collection was initiated in November
1998. As this was more than two years after study re-
cruitment started (September 1996), reduced numbers
of patients and samples were available at some time points.
Plasma samples were shipped at ambient temperature to a
central lab by overnight courier, where they were promptly
frozen at −70°C until being shipped frozen to the London
Regional Cancer Program laboratory for ELISA assess-
ment. Prior to initiation of plasma collection for the
MA.14 trial, in a pilot study to assess the potential effect of
this collection/storage process, we assessed OPN plasma
levels from eight blood samples maintained at room
temperature for 4 vs. 24, 48 or 72 hours, and found that
measured values did not differ with time at room
temperature. The total number of plasma samples avail-
able for OPN assays was 2,540, with 624 (94%) of 667
patients having plasma collected at some time. The
time-points for collection and numbers of available pa-
tients and samples are summarized in Table 1. Primary
statistical analyses utilized all samples at each time
point, but some exploratory analyses examined data
from paired samples for recurrent and non-recurrent
patients. Prognostic analyses examined baseline IHC
and plasma OPN effects on multiple survival out-
comes. To maximize inclusion of patients in these in-
vestigations and given the low likelihood of tumor
recurrence (2 in 388 patients) in the first four months
after randomization, we combined pre-randomization
and four-month results, giving a “baseline” assessment
of OPN in 388 (58%) of 667 patients. When there were
multiple assessment results for a patient during the
pre-randomization and four-month time-points, they
were averaged to yield a baseline OPN plasma value.
Table 1 Available samples
Total accrual 667 patients
Total patients with samples for OPN analyses
Plasma - baseline/4 m 388 (58%)
- any time 624 (94%)
Tumor tissue for IHC 462 (69%)
Total number plasma samples 2,540











*later protocol amendment eliminated these sample collections. IHC,
immunohistochemistry; OPN, osteopontin.
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to obtain primary tumor blocks/slides for OPN IHC in
462 (69%) of 667 patients accrued to MA.14. In total,
647 (97%) of patients had either measurement of OPN
in primary tumor (by IHC), or one or more measure-
ments of plasma OPN (by ELISA).
For comparison with MA.14 study samples, 90 plasma
samples from healthy women were collected under a
protocol approved by the University of Western Ontario
Research Ethics Board. Volunteer donors were hospital
staff who contributed blood samples for the purpose of
establishing normal levels of various blood components,
including OPN. The only data collected on these indi-
viduals were sex and age.
OPN analytic methods
OPN was measured in plasma samples by ELISA (Human
Osteopontin EIA Kit, catalogue #ADI-900-142, Enzo Life
Sciences, Ann Arbor, MI, USA) as previously described
[16]. This assay uses two monoclonal antibodies whose
epitopes have been defined [16]. It should be noted that
one of these antibodies recognizes an epitope that is
destroyed by thrombin cleavage and, thus, the ELISA can
be used with plasma but not with serum. Samples from
MA.14 were measured in duplicate and from healthy
women in triplicate, and the values for each sample were
averaged.
Formalin-fixed, paraffin-embedded primary tumor sam-
ples were assessed for OPN expression by IHC using an
immunoperoxidase technique, as previously described [7].The primary antibody used was the monoclonal antibody
mAb53 (Enzo Life Sciences, catalogue #ADI-905-629). Bi-
otinylated secondary antibody was from the LSAB2 kit
(Dako, Burlington, ON, Canada). Stained slides were eval-
uated by light microscopy in a blinded fashion by two pa-
thologists (ABT, WAK).
Tumor cell staining for OPN was determined as a con-
tinuous variable of the percentage of cells staining (re-
gardless of intensity), as well as using two different
semi-quantitative systems. The first was the non-linear
system of Allred et al. [17], which assigns proportion
and intensity scores as follows: proportion as the estimated
fraction of tumor cells staining (0 = none; 1 = <1/100; 2 = 1
to 10%; 3 = 10% to 1/3; 4 = 1/3 to 2/3; 5 = >2/3, and in-
tensity as the estimated average staining of tumor cells
(0 = none; 1 = weak; 2 =moderate; 3 = strong). The Allred
score is then the sum of proportion and intensity scores
(0 for negative staining and 2 to 8 for positive staining
ranges). The second, H-scoring system of McCarty
[18] is a linear system which quantifies the proportion
of tumor cells in each intensity category (0 = no staining;
1 = weak; 2 =moderate; 3 = strong). The percentage of
weakly stained cells is multiplied by 1, the percentage
of moderately stained cells by 2, and the percentage of
strongly stained cells by 3; the total of these three catego-
ries then gives the H-score (from 0 to a maximum of 300).
As OPN staining of tumor-infiltrating inflammatory cells
(histiocytes and T-lymphocytes) is generally intense in na-
ture, semi-quantitation of proportion of inflammatory
cells staining was performed using a 0 to 3+ system, such
that 0 = no staining of tumor infiltrating inflammatory
cells; 1+ = scattered OPN positive tumor infiltrating in-
flammatory cells, 2+ =moderate numbers of positive tu-
mor infiltrating inflammatory cells; and 3+ = numerous
positive tumor infiltrating inflammatory cells.
Definition of MA.14 endpoints
The primary end point of MA.14 was event-free survival
(EFS); secondary end points were relapse-free survival
(RFS) and overall survival (OS) [15]. As in a serum beta
C-terminal telopeptide study with MA.14 samples [19],
we also considered here bone and non-bone RFS. Cen-
soring was at the longest follow-up.
Statistical analysis
Our study utilized the MA.14 final analysis database, me-
dian follow-up 7.9 years. Baseline patient and primary tu-
mor characteristics are provided in Table 2. There were no
significant imbalances (P = 0.17 to P = 1.00) in treatment
arm or stratification factors for patients included in i)
tumor IHC OPN, ii) baseline plasma OPN, iii) primary
tumor IHC categorizations of recurrent or non-recurrent
and iv) plasma categorizations of recurrent or non-recur-
rent patients. Formal comparisons, to ensure that patients







Number % Number % Number %
Total 667 100 462 100 388 100
Age at allocation (yrs)
<60 329 49 220 48 193 50
≥60 338 51 242 52 195 50
Race
Caucasian 644 97 445 96 375 97
Not Caucasian 23 3 17 4 13 3
Performance status (ECOG)
0, unknown 520 78 362 78 305 79
1, 2 147 22 100 22 83 21
T pathologic classification
1, in situ 389 58 269 58 240 62
2, 3A, 4,
unknown
278 42 193 42 148 38
N pathologic classification
0 352 53 243 53 206 53




260 39 174 38 146 38
Other,
segmental
407 61 288 62 242 62
Number of positive nodes
0 352 53 243 53 206 53
1 to 3, 4+,
unknown




62 9 33 7 33 9
Positive 605 91 429 93 355 91
Adjuvant chemotherapy
None 445 67 312 68 236 61
Concurrent,
sequential
222 33 150 32 152 39
Tumor grade*
Unknown NA 0 0 84 22
1 NA 74 16 48 12
2 NA 232 50 150 39
3 NA 156 34 106 27
Histology*
No special type NA 446 97 290 75
Special type
(unknown)
NA 16 3 14 (84) 4 (22)
Table 2 MA.14 baseline patient and tumor characteristics
(Continued)
Lymphovascular invasion*
Unknown NA 0 0 84 22
No NA 414 90 274 71
Yes NA 48 10 30 8
NOTES: As there were no significant differences in survival outcomes in the
main MA.14 trial for Tamoxifen vs Octreotide, the two arms are combined.
*Only evaluated for OPN study.
ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; NA, not
available; OPN, osteopontin; PR, progesterone receptor.
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by treatment assignment and trial stratification factors of
lymph node status, receipt of adjuvant chemotherapy and
hormone receptor positivity, utilized exact Fisher tests.
Box-Cox transformations were considered for both
IHC OPN (percentage positive; Allred score; H-score)
and plasma OPN for variance stabilization transform-
ation and to improve the assumption of normality dur-
ing statistical tests; mean values and 95% confidence
limits (CI) reported here are back-transformations to la-
boratory units as follows: 1) IHC OPN percentage cells
staining (underwent Box-Cox power 0.5 transformation);
2) IHC OPN H-score (underwent Box-Cox power 0.5
transformation); 3) IHC Allred score 0 to 8 (no trans-
formation); 4) Inflammatory cell OPN, by intensity (0, 1,
2, 3); 5) Plasma OPN (logarithmic transformation). Box
plots were also performed on plasma levels in MA.14 for
patients at baseline; non-recurrent patients; and recur-
rent patients at baseline, prior to the recurrence period
and in the recurrent period.
Factors considered in exploratory time to event analyses
were the MA.14 baseline patient and tumor characteristics
[15], IHC and plasma OPN, and newly assessed pathologic
factors of tumor grade, histology and lymphovascular in-
vasion. Univariate analyses utilized a stratified log-rank
test, with adjustment by MA.14 trial stratification factors,
lymph node status, estrogen and progesterone receptor
status, and adjuvant therapy [15]; for consistency with our
previous study [7] and those of others [8-10], the univari-
ate cut-point for Allred score was 0 to 4 vs >4. Multivari-
ate analyses employed step-wise forward stratified Cox
regression, with P-values determined by the likelihood ra-
tio criterion, and a factor added if P ≤0.05 (χ2(1)). Factors
entered into the multivariate analysis included continuous
OPN, treatment arm, patient age, race, weight, body mass
index, Eastern Cooperative Oncology Group (ECOG) sta-
tus, tumor size and grade, lymph node status, surgery
type, lymphovascular invasion, IGF-1 and IGFBP-3 and
C-peptide. Pearson and Spearman correlation coefficients
were used to examine the association of primary IHC
OPN and baseline plasma OPN. Individual patient dif-
ferences in plasma OPN between clinical windows were
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and then individual patient values were back-transformed
to laboratory units for plots connecting patient values for
different clinical windows.
Normative plasma OPN values were established with 90
female healthy controls, age range 19 to 59 years, assessed
in triplicate and averaged. Population OPN levels were
characterized with Box plots for OPN in healthy women.
Results
Based on our original hypotheses and the inventory of
samples, our specific aims were 1) to evaluate whether
baseline/four-month plasma OPN levels were prognostic
for EFS, RFS, bone or non-bone RFS and OS; 2) to
evaluate whether primary tumor OPN IHC levels were
prognostic for EFS, RFS, bone or non-bone RFS and OS;
3) to explore whether tumor OPN expression was asso-
ciated with baseline plasma OPN levels; 4) to explore in-
dividual patient changes in plasma OPN from baseline/
4 months to recurrence. For aim 4) we utilized clinical
windows to group individual patient OPN values: (a) base-
line (pre-randomization/4 months); (b) recurrent cases
(Period 1: 8 months after randomization to 18 months
prior to recurrence; Period 2: <18 months from recur-
rence until collection stopped), (c) non-recurrent cases
(baseline/4 months; any other time).
In the 90 healthy women, mean plasma OPN was
28.4 ng/ml, median 26.3 and range 11.8 to 109. The
upper 97.5% cut-point was 95 ng/ml. There was only a
weak correlation of OPN with age (Pearson correlation
coefficient 0.20, P = 0.06; Spearman correlation coeffi-
cient 0.26, P = 0.02), with a trend for increasing OPN
levels with rising age (Additional file 1: Figure S1). The
values obtained in this larger sample of healthy women
are consistent with results from our previous cohort of
35 pre- and post-menopausal healthy women, median
OPN 47 ng/ml), range 22 to 122 [11,12]. Although the
median value was higher in the earlier cohort, the upper
limits of the range are quite similar.
As outlined in Table 1, plasma OPN was measured
in 2,540 plasma samples. In total, 624 (94%) patients
had OPN results at some time. The geometric mean for
baseline plasma OPN level, in 388 women, was 46 ng/ml
(range 22.6 to 290; Additional file 2: Figure S2 (top, bot-
tom), plotted versus IHC OPN, as both percentage cells
staining and H-score). The geometric mean for 193
women allocated tamoxifen was 45.3 ng/ml (95% CI:
43.4 to 47.3 ng/ml), and for 195 women allocated tam-
oxifen with octreotide LAR, 46.8 ng/ml (95% CI: 44.5
to 49.1 ng/ml). Seven women (1.8%) had baseline values
above 95 ng/ml, and only three women (0.8%) had base-
line values above 122 ng/ml, our previously reported
[11,12] upper limit of normal OPN levels (147.7, 265.1,
289.8 ng/ml). The few patients with high baselineplasma OPN were not observed to have any specific
stratification factor profile. The mean cut-point for
baseline plasma OPN level, in univariate analysis, did
not show any association with EFS (P= 0.85), RFS (P = 0.28),
OS (P = 0.06), bone RFS (P = 0.23) and non-bone RFS
(P = 0.45), nor was it significant in the multivariate model.
Figure 1 visually compares OPN levels (mean (range)
in ng/ml) across six groups, using data from the max-
imum number of samples available at each time-point.
Healthy women (A = 90 women) 28.4 (11.8 to 109) are
compared with breast cancer patients in MA.14; those
who never had recurrence, at baseline (B = 304 pts) 46.0
(22.6 to 290) and after baseline (E = 456 pts) 43.9
(19.2 to 564); and those who had recurrence, at baseline
(C = 84 pts) 46.2 (22.8 to 98.1), in Period 1 (D = 100 pts)
42.8 (25.6 to 92.2) and Period 2 (F = 80 pts) 60.7 (23.9 to
563). In Figure 1, the boxes show OPN values between the
25th and 75th percentiles, with whiskers showing ranges.
There is a wider spread of OPN values above the median
in samples measured during recurrence (Period 2) in the
80 patients who experienced recurrence (Group F). Three
of 490 (0.6%) patients who never had recurrence had
OPN levels >122 ng/ml at any time, and 8 of 80 (10%)
with recurrence had OPN levels >122 ng/ml, all during
the recurrent Period 2. A plot (data not shown) including
only patients with paired samples in Groups B, E (270 pa-
tients) and C, D, F (31 patients) showed a similar distribu-
tion of OPN levels.
Figure 2 graphically shows individual patient changes
in plasma OPN for 66 patients with recurrence, from
the time period prior to recurrence (Period 1) to the re-
currence period (Period 2), who had samples available in
both time periods. A matched t-test indicated a signifi-
cantly higher plasma OPN in the recurrent period (mean
57.3 ng/ml) than at baseline/4 months (mean 46.4 ng/ml)
(P = 0.002).
When tumor tissue OPN positivity was defined and
assessed as the percentage of cells staining by IHC as a
continuous variable (regardless of intensity), of the 462
primary tumors assayed, the mean percentage of OPN
tumor cell positivity was 33.9 (95% CI: 30.2 to 37.9), and
was not significantly different for 105 patients who sub-
sequently developed recurrence (32.4 (95% CI: 24.6 to 41.2))
and the 357 who did not (34.4 (95% CI: 30.2 to 38.8)).
In univariate analyses of tumor tissue OPN, when defined
and assessed as the percentage of cells staining by IHC,
there was no association between primary tumor OPN
expression with cut-point at mean and EFS (P = 0.34), RFS
(P = 0.88), OS (P = 0.62), bone RFS (P = 0.74) or non-bone
RFS (P = 0.96), nor was inflammatory cell OPN associated
with any endpoint (respectively, P = 0.55, 0.26, 0.10, 0.27,
0.75). Similar results were obtained when OPN was
assessed by H-score. Using an Allred score cut-point < =4
vs > =5, primary tumor OPN expression was not associated
Characterization of plasma OPN by group
A (n = 90) B (n = 304) C (n = 84) D (n = 100) E (n = 456) F  (n = 80)
Group
A – Healthy women
B – Non-recurrent patients at baseline
C – Recurrent patients at Baseline
D – Recurrent patients prior to recurrence period
E – Non-recurrent patients after baseline












Figure 1 Characterization of plasma OPN by group. This figure visually compares plasma OPN levels of healthy women (A = 90 pts) with
levels in women who never had recurrence, at baseline (B = 304 pts) and after baseline (E = 456 pts); and with levels in women who had
recurrence, at baseline (C = 84 pts), in Period 1 (D = 100 pts) and Period 2 (F = 80 pts). The boxes show OPN values between the 25th and 75th
percentiles, with whiskers showing ranges. OPN, osteopontin.
Bramwell et al. Breast Cancer Research 2014, 16:R8 Page 6 of 10
http://breast-cancer-research.com/content/16/1/R8with any survival endpoint (respectively, P = 0.24, 0.95, 0.20,
0.79, 0.94). Higher tumor grade (HR 1.90, P <0.0001), older
age (HR 1.68, P = 0.0004), higher pathological tumor stage
pT (HR 1.65, P = 0.0005) and higher pathological node
stage pN (HR 9.02, P = 0.0026) categories had significantly










Figure 2 Average OPN plasma levels in recurrent period vs non-recur
patient changes in plasma OPN for 66 patients with recurrence, from the t
(Period 2), who had samples available in both time periods. OPN, osteoponwith RFS and OS; tumor grade, age and pT were similarly
associated with bone RFS; and tumor grade and pN with
non-bone RFS.
In the multivariate EFS Cox model, high tumor grade
(HR 1.72, P <0.0001), age >60 yrs (HR 1.47, P = 0.02),
higher body mass index (HR 1.55, P <0.0001) andPN by period
Recurrence
d
rent period for 66 patients. This figure graphically shows individual
ime period prior to recurrence (Period 1) to the recurrence period
tin.
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significantly associated with worse EFS. Primary IHC
tumor expression of OPN (the percentage of cells stain-
ing, H-score, Allred score) and inflammatory cell OPN,
as well as baseline plasma OPN level, were not signifi-
cantly associated with EFS in the multivariate model.
Additionally, none of the OPN factors were associated
with RFS, OS, bone RFS or non-bone RFS.
Neither mean percentage OPN staining by IHC nor
mean baseline OPN plasma level differed significantly by
T stage (T0-1 vs T2 to 4), tumor grade (1 vs 2 vs 3),
nodal status (negative vs positive), hormone receptor
status (negative vs positive), age (<60 years vs older),
race (Caucasian vs other), or body mass index (in quar-
tiles). Baseline plasma OPN levels were not correlated
with primary tumor OPN expression (Pearson coeffi-
cient 0.02, P = 0.73; Spearman coefficient 0.05, P = 0.42).
Discussion
Our correlative marker study of OPN in the setting of
the MA.14 prospective clinical trial was designed in
1998, and the protocol was developed based on data
from experimental and clinical studies conducted by our
group over several years [7,11,12,20-22]. At that time,
OPN as a potential tumor marker in breast cancer fit
into the category “+” on the Tumor Marker Utility Grad-
ing System (TMUGS) proposed by Hayes et al. [23], de-
fined as “sufficient data are available to demonstrate that
the marker correlates with the biologic process and/or
biologic endpoint related to the use and that the marker
results might affect favourable clinical outcome for that
use. However, the marker is still considered investiga-
tional and should not be used for standard clinical prac-
tice…”. In July 1997, we had opened a prospective
clinical study evaluating the prognostic value of measur-
ing serial OPN levels in women with metastatic breast
cancer [14]. The current study was intended to be com-
plementary, and extend our investigations to early breast
cancer taking advantage of the infrastructure of an exist-
ing prospective clinical trial that included collection of
primary tumor blocks, and serial blood samples. The de-
sign of this correlative study meets the criteria for Level
II evidence in the system proposed by Hayes et al. [23] for
“Levels of evidence for grading clinical utility of tumor
markers”, which outlined a scale of I to V, with Level I pro-
viding the best evidence. In 2005 (and updated in 2012),
McShane et al. published a paper entitled “Reporting Rec-
ommendations for Tumor Marker Prognostic Studies”
[24,25], and although this MA.14 correlative study was de-
signed several years earlier, we have endeavored to follow
these recommendations in reporting our results.
In our pilot study [7], tumor cell OPN IHC staining
above an optimized cut-point using the Allred scoring
system was significantly associated with decreased DFSand OS in univariate analysis, but only with decreased
OS in multivariate analysis (including patient age, meno-
pausal status, tumor size, grade hormone receptor status
and p53 positivity). Similarly, Rudland’s group has re-
ported that OPN positivity in breast tumor tissue (de-
fined as >5% cells staining by IHC), in women with
operable Stage I and II breast cancer, was associated
with shorter survival [8,9]. In multivariate analysis, our
current study shows no significant association between
tumor cell OPN expression, scored in several different
ways, and any survival outcome. These findings differ
from our previous pilot study [7] and those of others
[8-10]. The MA.14 trial is larger than previous studies,
and recruited a uniform population of postmenopausal
women with hormone receptor positive tumors. In pre-
vious studies all patients were diagnosed before 1996
(sometimes as far back as 1972) when recruitment
started for the MA.14 trial. Better systemic treatments in
the modern era, which are associated with steadily im-
proving survival in women with early breast cancer [26],
may have reduced the adverse effects of OPN in primary
tumors, accounting for the discrepancy between studies.
In addition, the patients in this study are all postmeno-
pausal, most are ER or PR positive, and all received tam-
oxifen. It is possible that OPN may not have the same
prognostic significance in this subgroup of patients. In
particular, little is known about how tumor cell OPN ex-
pression is affected by estrogen antagonists, although it
is known that the OPN promoter can respond to both
estrogen receptor alpha and estrogen-related receptor
[27-29]. If OPN is indeed down-regulated by tamoxifen
use, its prognostic impact in this patient population may
have been negated by the therapy.
In our first study of plasma OPN in 35 healthy female
volunteers, the median level was 47 μg/L (47 ng/ml)
with a range 22 to 122 ng/ml, with no significant differ-
ences in premenopausal versus postmenopausal women,
or according to menstrual status [11,12]. In 44 women
who had completed treatment for early breast cancer at
least six months earlier, the range of values was similar,
15 to 117 μg/L, but the median level was higher at
60 μg/L [11]. The mean baseline OPN level of 46.0 ng/ml
in MA.14 is very similar to the median level we reported
for healthy women [11]. We have also shown a similar
range of OPN values in 26 healthy male volunteers, me-
dian 56 ng/ml, range 26 to 98, using the same ELISA sys-
tem (Thoms et al. [30], Supplemental file, Table 3a in
[30]). As all baseline samples for MA.14 were taken within
12 months of primary surgery (for those receiving adju-
vant chemotherapy), or within 6 months (no chemother-
apy), and this was a population at relatively low risk for
recurrence, it is likely that these baseline OPN levels rep-
resent a true disease-free (or microscopic residual) state.
The 44 women in our pilot study [11] were clinically
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blood for OPN was taken at variable intervals (months to
years) after the primary diagnosis. These women were not
followed subsequently to determine if and/or when they
suffered relapse, with the possibility that some had active
subclinical recurrence, which may account for the higher
median OPN level (60 ng/ml) compared with healthy
volunteers. Thus, in MA.14 it is not necessarily sur-
prising that the mean OPN level of 60.7 ng/ml ob-
served during the recurrence period, for women who
developed recurrence, is similar to that found in non-
recurrent patients in our pilot study.
In our current study of 90 healthy women, the max-
imum plasma OPN level was 109 ng/ml, and in healthy
male volunteers it was 98 ng/ml [30]. In our first study
of healthy female controls, the maximum OPN value
was 122 ng/ml [11]. Based on the highest value we have
seen in normal controls (122 ng/ml), elevated baseline
OPN levels were only seen in 3 of 388 (0.8%) of the
women in MA.14. It is interesting that these three pa-
tients were in Group B and did not develop recurrence
during the follow-up period of the trial. Thus, our re-
sults do not suggest that baseline plasma OPN is a use-
ful prognostic marker in this patient population. Our
results further did not find an association between levels
of OPN in plasma at baseline and tumor tissue in this
cohort, perhaps due to the finding that the vast majority
of baseline plasma OPN values were not elevated above
normal levels.
However, serial assays in MA.14 have provided some
intriguing hints about OPN as a marker of recurrence/
metastasis. As shown in Figure 1, a higher median and
upward spread of OPN levels are seen in Group F pa-
tients, those with recurrence during the recurrence
period, in comparison to the same patients prior to re-
currence (Groups C and D). Several patients in Group F
had very high OPN levels (maximum 563 ng/ml). We
speculate that high OPN levels during follow-up in some
Group E patients, without documented recurrence, could
in fact represent recurrence as yet undetected clinically.
Elevated plasma levels of OPN are associated with poor
prognosis in patients with metastatic breast cancer. The
present study suggests that baseline OPN plasma levels in
postmenopausal patients with hormone responsive early
breast cancer receiving tamoxifen may not have the same
prognostic value. However, the elevated plasma OPN
levels seen in some patients post-baseline suggests that
serially monitoring of OPN levels may be of use as an
early indicator of relapse.
Our OPN study has several strengths. There were
strong preclinical and some clinical data supporting our
interest in exploring OPN as a clinical biomarker in
breast cancer in the metastatic setting, but its role in
early stage disease was relatively unexplored. The patientpopulation accrued to the MA.14 trial was well defined,
and details are given in the final trial report [15]. Multiple
patient and tumor prognostic factors were collected, and
could be entered in multivariate analyses. Our assays are
well validated and reported [7,11,16]. We developed pre-
specified hypotheses, and a correlative study plan that was
compatible with the trial protocol. The results of our IHC
and plasma OPN assays were provided to the NCIC CTG
MA.14 study statistician (JWC), who developed the de-
tailed statistical plan and performed the analyses.
Our current study also has several limitations - the
relatively short duration of sample collection (five years)
at a time when improved treatments for breast cancer
may have delayed or even prevented relapse; wide spa-
cing of samples after the first year (every 12 months);
and the small numbers of samples (22 in 20 patients) ac-
tually obtained at the documented time of relapse. After
definitive treatment of primary breast cancer, loco-
regional recurrence and/or metastasis will be subclinical
for a variable period of time (depending on aggressive-
ness) before the date of recurrence is documented for
trial outcomes. Thus, we defined a recurrence time win-
dow (samples collected up to 18 months before recur-
rence) which expanded the number of available samples
for statistical purposes, but may have blunted the com-
parison of OPN levels between baseline and recurrence.
Additionally, the ELISA used here, although clinically
validated [7,11,16], may detect only a subset of total
blood OPN, for example, not proteolytic fragments of
OPN or OPN bound to Factor H [31]. Finally, this trial
provides no information about plasma OPN levels before
removal of primary breast cancer, as all women had
undergone definitive surgery before entering the MA.14
trial and providing their first blood sample. The timing
of the baseline samples may also explain the lack of cor-
relation between primary tumor expression of OPN and
mean baseline plasma OPN level.
Our hypothesis that there would be a relationship be-
tween baseline tissue and plasma levels of OPN was not
supported by our data. Given that blood OPN levels can
come from many sources (tumor tissue, remodeling vas-
culature, inflammatory cells and bone [1,2,5]), and vary
with the timing of baseline samples post-resection of
primary breast cancer, this finding is perhaps not sur-
prising. Similarly, our hypothesis that tissue and plasma
levels would have prognostic value in early breast cancer
was not supported in multivariate analysis. This differ-
ence from previous studies may be due to improved
overall prognosis for women with early breast cancer as-
sociated with better adjuvant treatments. In addition, or
alternatively, the difference may be related to the specifics
of the present population (postmenopausal, mainly ER/PR
positive, receiving tamoxifen) and the possible estrogen-
sensitivity of the OPN promoter. Finally, the elevation of
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current and non-recurrent patients (some of whom might
have recurred at a later date), suggests that there may be a
role for serial measurement of plasma OPN to monitor
for recurrence, in the setting of early breast cancer. This
latter idea is worthy of further study.
Conclusions
Elevated levels of osteopontin (OPN) protein in plasma or
tumors from metastatic breast cancer patients have been
associated with poor survival. OPN thus has been pro-
posed as a biomarker of breast cancer progression. How-
ever, little was known about its prognostic significance in
early breast cancer. Here, we measured OPN in tumor tis-
sue and serial plasma samples from hormone responsive
patients with early breast cancer enrolled in the MA.14
trial. In multivariate analysis neither plasma nor tumor
OPN provided prognostic information. Thus, tumor or
plasma OPN levels may be of limited prognostic value in
postmenopausal hormone responsive early breast cancer,
although this would need to be confirmed on a broader pa-
tient population. However, our finding of elevated plasma
OPN in post-baseline samples of a small number of pa-
tients suggests that further studies exploring OPN plasma
levels around the time of recurrence would be worthwhile.
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healthy women.
Additional file 2: Figure S2. Plot of baseline plasma OPN in 388
women vs. tissue OPN measured by IHC. Top panel, OPN tissue levels
measured as the percentage of cells staining; Bottom panel, OPN tissue
levels measured as H-score.
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